Analysis of determination of rabies virus neutralizing antibody titres in the sera of vaccinated humans

Cover Page


Cite item

Full Text

Abstract

Introduction. Rabies is an infectious disease that is always fatal following the onset of clinical symptoms. The only way to prevent the cases of rabies in humans is timely carried out the rabies post-exposure prophylaxis in accordance with the recommended schedule.
The aim of the study was to characterize the level of immune response in persons that received a post-exposure prophylaxis against rabies, to consider the role of the factors of the formation immune responses to rabies vaccines .
Material and methods. In the laboratory of viral vaccines of the Scientific Centre for Expert Evaluation of Medicinal Products, the 48 sera of patients that received the post-exposure prophylaxis of rabies after wounds from a rabid or suspected rabid animal has been studied. The titer of virus neutralizing antibodies (VNA) to the rabies virus in the sera of the vaccinated not less than 1:64 (corresponding to a level of VNA at least 0,5 IU /ml) in the mouse neutralization test indicates the effective vaccination.
Results and discussion. Our data confirm the absence of statistically significant differences in the level of VNA in the vaccinated persons that received a complete and incomplete (5 doses) course of post-exposure vaccination against rabies. Depending on the level of VNA, all patients are divided into groups with conditionally low, medium and high content of antibodies in sera.
Conclusion. It has been shown that in most cases properly administered vaccination contributed to the formation of effective immune response. The lack of a protective level of BHA requires additional administration of the vaccine and analysis of the factors that influenced the ineffectiveness of vaccination. In some patients the determination of rabies virus neutralizing antibody titres is necessary.

About the authors

A. Yu. Butirskiy

Scientific Centre for Expert Evaluation of Medicinal Products

Author for correspondence.
Email: Butirskiy@expmed.ru
ORCID iD: 0000-0002-0352-522X
leading expert of viral vaccines laboratory

Moscow, 127051 Россия

A. V. Muhacheva

Scientific Centre for Expert Evaluation of Medicinal Products

Email: fake@neicon.ru
ORCID iD: 0000-0003-0769-6867
Moscow, 127051 Россия

A. A. Movsesyants

Scientific Centre for Expert Evaluation of Medicinal Products

Email: fake@neicon.ru
ORCID iD: 0000-0003-2132-0962
Moscow, 127051 Россия

K. A. Sarkisyan

Scientific Centre for Expert Evaluation of Medicinal Products

Email: fake@neicon.ru
ORCID iD: 0000-0003-0445-7086
Moscow, 127051 Россия

References

  1. Шабейкин А.А., Зайкова О.Н., Гулюкин А.М. Обзор эпизоотической ситуации по бешенству в Российской Федерации за период с 1991 по 2015 годы. Ветеринария Кубани. 2016; (4): 4-6.
  2. Шабейкин А.А., Гулюкин А.М., Хисматуллина Н.А., Цареградский П.Ю., Паршикова А.В., Rob van Herwijen. Обзор эпизоотической ситуации бешенства, сложившейся в Российской Федерации в 2014 году. Ветеринария и кормление. 2015; (2): 19-23.
  3. Мовсесянц А.А., Олефир Ю.В. Современные проблемы вакцинопрофилактики бешенства. БИОпрепараты. Профилактика, диагностика, лечение. 2019; 19(1): 10-6. Doi: https://doi.org/10.30895/2221-996X-2019-19-1-10-16
  4. Никифоров В.В., Авдеева М.Г. Бешенство. Актуальные вопросы. Эпидемиология и инфекционные болезни. 2017; 22(6): 295-305. Doi: https://doi.org/10.18821/1560-9529-2017-22-6-295-305
  5. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine. 2010; 28(23): 3896-901. Doi: https://doi.org/10.1016/j.vaccine.2010.03.039
  6. Jones R.L., Froeschle J.E., Atmar R.L., Matthews J.S., Sanders R., Pardalos J., et al. Imminogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with diploid cell rabies vaccine. Vaccine. 2001; 19(32):4635-43. Doi: https://doi.org/10.1016/s0264-410x(01)00238-9
  7. Briggs D.J., Dreesen D.W., Nicolay U., Chin J.E., Davis R., Gordon C., et al. Purified chick embryocell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one- versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine. 2000; 19(9-10): 1055-60. Doi: https://doi.org/10.1016/s0264-410x(00)00342-x
  8. Wiktor T.J., Plotkin S.A., Grella D.W. Human cell culture rabies vaccine: antibody response in man. JAMA. 1973; 224(8): 1170-1.
  9. Bernard K.W., Roberts M.A., Sumner J., Winkler W.G., Mallonee J., Baer G.M., et al. Human diploid cell rabies vaccine: effectiveness of immunization with small intradermal or subcutaneous doses. JAMA. 1982; 247(8): 1138-42. Doi: https://doi.org/10.1001/jama.247.8.1138
  10. Rupprecht C.E., Nagarajan T., Ertl H. Rabies vaccines. In: Plotkin S.A., Orenstein W., Offit P.A., Edwards K.M., eds. Vaccines. Philadelphia: Elsevier; 2017.
  11. Mastroeni I., Vescia N., Pompa M.G., Cattaruzza M.S., Marini G.P., Fara G.M. Immune response of the elderly to rabies vaccines. Vaccine. 1994; 12(6): 518-20. Doi: https://doi.org/10.1016/0264-410x(94)90310-7
  12. Leder K., Weller P.F., Wilson M.E. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin. Infect. Dis. 2001; 33(9): 1553-66. Doi: https://doi.org/10.1086/322968
  13. Mansfield K.L., Burr P.D., Snodgrass D.R., Sayers R., Fooks A.R. Factors affecting the serological response of dogs and cats to rabies vaccination. Vet. Rec. 2004; 154(14): 423-6. Doi: https://doi.org/10.1136/vr.154.14.423
  14. Rotivel Y., Weber P., Goudal M. Post-exposure treatment of patients with impaired or suboptimal immunity. In: Dodet B., Meslin F.X., eds. Rabies Control in Asia. Proceedings of the Fourth International Symposium, Hanoi, Viet Nam. Paris: John Libbey Eurotext; 2001: 61-5.
  15. Thisyakorn U., Pancharoen C., Wilde H. Immunologic and virologic evaluation of HIV-1-infected children after rabies vaccination. Vaccine. 2001; 19(11-12): 1534-7. Doi: https://doi.org/10.1016/s0264-410x(00)00322-4
  16. Briggs D.J., Schwenke J.R. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine. 1992; 10(2): 125-9. Doi: https://doi.org/10.1016/0264-410x(92)90029-j
  17. Jaijaroensup W., Tantawichien T., Khawplod P., Tepsumethanon S., Wilde H. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 1999; 28(4): 913-4. Doi: https://doi.org/10.1086/517241
  18. Deshmukh R.A., Yemul V.L. Fatal rabies encephalitis despite postexposure vaccination in a diabetic patient: a need for use ofrabies immune globulin in all post-exposure cases. J. Assoc. Physicians India. 1999; 47(5): 546-7.
  19. Abazeed M.E., Cinti S. Rabies prophylaxis for pregnant women [letter]. Emerg. Infect. Dis. 2007; 13(12): 1966-7. Doi: https://doi.org/10.3201/eid1312.070157.
  20. Sudarshan M.K., Madhusudana S.N., Mahendra B.J. Post-exposureprophylaxis with purified Vero cell rabies vaccine during pregnancy: safety and immunogenicity. J. Commun. Dis. 1999; 31(4): 229-36.
  21. Mansfield K.L., Andrews N., Goharriz H., Goddard T., McElhinney L.M., Brown K.E., et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine. 2016; 34(48): 5959-67. Doi: https://doi.org/10.1016/j.vaccine.2016.09.058
  22. Селимов М.А. Бешенство. М.: Медицина; 1978.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Butirskiy A.Y., Muhacheva A.V., Movsesyants A.A., Sarkisyan K.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies